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In early 2020, a novel coronavirus leading to potentially death was discovered. Since then,
the 2019 coronavirus disease (COVID-19) has spread to become a worldwide pandemic.
Beyond the risks strictly related to the infection, concerns have been expressed for the
endocrinological impact that COVID-19 may have, especially in vulnerable individuals with
pre-existing endocrinological health conditions. To date new information is emerging
regarding severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) in
children but the literature is still scarce concerning this infection in patients with intracranial
malignant neoplasms. We report a 9-year-old child infected with SARS-CoV-2 and recent
diagnosis of suprasellar non-germinomatous germ cell tumor also suffering from diabetes
insipidus and hypothalamic-pituitary failure (hypothyroidism, adrenal insufficiency,
hypothalamic obesity and growth hormone deficiency) and its clinical course. The
patient remained asymptomatic for the duration of the infection without requiring any
change in the replacement therapeutic dosages taken before the infection. We then
discuss the proposed approach to treat a pediatric patient with SARS-CoV-2 infection
and hypothalamic-pituitary failure and we include a review of the literature. Our report
suggests that SARS-CoV-2 infection is usually mild and self-limiting in children even those
immunocompromised and with multiple endocrinological deficits. Patients are advised to
keep any scheduled appointments unless informed otherwise.
Keywords: Sars-CoV2, COVID-19, GNS germ cell tumor, pediatric endocrinology, diabetes insipidus, hypothalamic-
pituitary failureINTRODUCTION
The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which first appeared in
December 2019 in Wuhan, has caused the coronavirus disease 2019 (COVID-19) related pandemic
and has been declared a significant threat to international health by the World Health Organization.
Based on data from large studies, obesity emerged as a strong and independent determinant of
increased risk of morbidity andmortality in adult patients infected with SARS- CoV-2 (1) and patients
with cancer have a higher risk of worse outcomes with increased risk of severity and mortality. As inn.org March 2021 | Volume 12 | Article 5966541
Gaudino et al. Case Report: SARS-CoV-2 in a Child With Pituitary Failureadults, but less frequently, children with comorbidities as
malignancies, diabetes, obesity and immune disorders, are more
likely to develop severe conditions from COVID-19 (2).
Management of patients with pituitary tumors and their
associated hormonal abnormalit ies and mass effect
complications can be challenging even during normal times and
need to be preferably handled in Pituitary Centers of Excellence,
with a multidisciplinary approach, especially in complex cases.
Some of the diagnostic and management dilemmas regarding
adult patients with pituitary tumors, and guidance on safe and as
effective as possible delivery of care in the COVID-19 era, are have
recently been reported (3). Indeed, evidence suggests that SARS-
CoV-2 infection in children with oncological comorbid and
endocrinological health problems may be challenging in terms
of management and could require complex care.Frontiers in Endocrinology | www.frontiersin.org 2CASE DESCRIPTION
We report the case of a 9-year-old Caucasian female affected by
suprasellar non-germinomatous germ cell tumor (NGGCT)
associated with multiple pituitary deficit, who tested positive
for SARS-CoV-2 an April 1, 2020.
Her problem began 2 years earlier, with polyuria, polydipsia
(she drank almost 8 liters of water/day) and growth delay. In
October 2019, she came to Verona’s Paediatric Emergency
Department in a state of confusion. Brain magnetic resonance
imaging revealed a suprasellar mass, compatible with germinoma
(Figure 1). This hypothesis was confirmed by high levels of alfa-
fetoprotein and human chorionic gonadotropin (hCG) in plasma
and cerebrospinal fluid (CFS). Based on alfa-fetoprotein and
hCG levels the tumor was classified as a non germinomatousFIGURE 1 | Brain magnetic resonance imaging at the time of diagnosis. There is a recognizable, voluminous expansive lesion at the hypothalamic level (A, FLAIR
sequence) with an inhomogeneous structure, first read as calcifications (B, T1 sequence; C, T2 sequence). Optic chiasma, hypothalamic-pineal peduncle and
mammillary body are not recognizable. (D, T2W_TSE sequence).March 2021 | Volume 12 | Article 596654
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study of visual fields were normal. At the time of diagnosis, blood
exams tests confirmed a multiple pituitary deficit with diabetes
insipidus, central hypothyroidism, hypocortisolism, growth
hormone deficiency and mild hyperprolactinemia. The
patient’s laboratory test results at time of diagnosis are shown
in Table 1. The girl started therapy with levothyroxine (initially
at dosage 25 mcg/day) and desmopressin (initially intranasal,
then sublingual). She was given dexamethasone after the MRI to
reduce tumoral edema. Over the next few days the patient was
found to have “cerebral salt wasting” with hyponatremia, high
urinary sodium excretion (129 mmol/L) and persistent polyuria,
so we started fludrocortisone. It was stopped after four days
when laboratory tests normalized. She continued therapy with
desmopressin, levothyroxine and hydrocortisone and the patient
had periodical laboratory tests and therapeutic adjustments.
In October 2019 chemotherapy according to SIOP CNS GCT
II standard risk protocol for non-germinomatous germ cell
tumor (NGGCT) was started. The first cycle was complicated
by hydrocephalus that required ventricular-peritoneal
derivation. At the end of the third cycle, the MRI showed a
partial response to chemotherapy. Therefore, in January 2020,
the patient underwent neurosurgery. The histopathological
examination was conclusive for immature teratoma. Follow-up
MRI one month after surgery showed a suspected small residual
lesion. Chemotherapy with high-dose etoposide was started.
From the 8 March, the “lockdown” for all Italy was adopted
together with the use of surgical mask, hand hygiene, and social
distancing, to prevent the massive spread of SARS-CoV-2;
moreover, a screening program by nasopharyngeal swab (NPS)
for any patient and caregiver parent accessing the Pediatric
Hematology Oncology Unit was started (4). On March 12, the
patient (and her mother) underwent the NPS and both resulted
negative for SARS-CoV-2. She was taking desmopressin (sublingual
tablets 60 mcg, 2 + 1+2, 300 mcg/day), levothyroxine at 75 mcg/day
and hydrocortisone at 8,92 mg/m2.day divided into 2 doses.Frontiers in Endocrinology | www.frontiersin.org 3Therapy with recombinant GH was not yet started. Since her
neurosurgical operation, she suffered from hypothalamic obesity
(incontrollable hyperphagia, decreased satiety and decreased
physical activity) with massive weight gain.
On March 5 she was admitted to the Pediatric Oncology Unit
for mobilization chemotherapy with high-dose etoposide and
granulocyte colony-stimulating factor (G-CSF) followed by
peripheral stem cell collection for autologous stem-cell
transplantation (ASCT). On April 1 she was admitted to the
Pediatric Oncology Unit for ASCT. Her weight was 40,9 kg
(93,21 percentiles based on Cacciari’s charts) and her height was
120,2 cm (6,08 percentiles based on Cacciari’s charts), with a
BMI of 28,31 kg/m2 (99,06° centiles based on Cacciari’s charts).
When she came for screening, a second NPS for SARS-CoV-2
was performed on the patient and parent caregiver (the father)
and both resulted positive. The pre-transplant conditioning
regimen (HD PEI cycle - cisplatin, etoposide and ifosfamide-
according to SIOP CNS GCT II protocol) was already started on
April 2 in the morning, and was therefore withdrawn as soon as
the result of NPS was communicated in the evening of the same
day (administration of day 1 of conditioning regimen). Both
patient and father were quarantined in a pediatric COVID19
section of the department to monitor the patient’s symptoms or
signs of SARS-CoV-2 infection. During observation, blood
count, urine tests. inflammatory markers, chest X-ray were
unremarkable. In particular, her blood exams showed
leukocytes 6,87x10^9/L, neutrophils 5,77x10^9/L and
lymphocytes 0,40x10^9/L. No respiratory, cutaneous signs, or
fever appeared during recovery and the patient continued her
previous therapies. The most significant laboratory tests before,
during and after Sars-Cov2 infection are summarized in Table 2.
Her diuresis remained in the range of 2-2,9 ml/kg/h. The patient
was discharged 3 days later, in good general conditions. Her
weight at discharge was stable. Another two nasal and
pharyngeal swabs were both negative after 28 days (Table 3).
The ASCT was performed on April 30 after a conditioning
regimen with high dose ifosfamide, etoposide and cisplatin.
She received 4.38 x 106/kg CD34+. The patient engrafted on
day + 9 for neutrophil and on day + 12 for platelets and was
discharge home in good clinical conditions. In accordance with
Verona University and University of Verona Institutional review
Board (IRB) policies, case reports are not considered to be
research subject to IRB review and are thus except from formal
IRB approval for publication. Written informed consent was
obtained from the patient’s legal guardians for the publication of
any potentially identifiable images or data included in this article.DISCUSSION
Our case report, for the first time, describes the evolution of SARS-
CoV-2 infection in a child with intracranial malignant neoplasms
and multiple pituitary failure. Clinical features of SARS-CoV-2
infection in adults have been reported elsewhere. Compared to
adult patients, reported cases of pediatric patients had clinically
milder symptoms and showed fewer alterations in radiological and
laboratory testing parameters. A systematic review confirmed thatTABLE 1 | Laboratory tests and physical examination at the time of diagnosis.
Laboratory test Normal values
Copeptin (pmol/L) <0,9 1.5-12.0
ACTH (pg/mL) <0.84 1.8-13.2
P-osmolality (mOsm/kgH2O) 292 275-295
Na (mmol/L) 147 135-145
Cortisol (nmol/L) 25 133-537
HPRL (ug/L) 35 4-23
IGF1 (ng/mL) 52,85 68,84-230
TSH (mUI/L) 0,41 0.30-4.20
fT4 (pmol/L) 6,7 11.0-22.0
U-osmolality (mOsm/kgH2O) 92 50-1200
U-Na (mmol/L) 29
alfa-fetoprotein (plasma) (ng/mL) 589.83 1,09-8,04
alfa-fetoprotein (liquor) (Index) 303 <1
hCG (plasma) (IU/L) 815 <5
hCG (liquor) (Index) 12 <9
Physical examination Centiles (Cacciari’s charts)
Weight (kg) 23 16,01°
Height (cm) 119 8,49°
BMI (kg/m2) 16,24 39,04°March 2021 | Volume 12 | Article 596654
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and recovered within 1 to 2 weeks after disease onset, and no cases
of pediatric death from COVID-19 were reported in the age range
of 0 to 9 years. One death was reported in the 10 to 19 years range,
but no further information was provided on this patient (5).
Primary central nervous system (CNS) germ cell tumors
(GCT) are a heterogeneous group of tumors that are still
poorly understood. Most of these tumors develop along the
midline, mainly from the pineal gland, followed by tumors
arising in the suprasellar cistern (6). The suprasellar region is
the second most common location of intracranial germinomas
and it has been clear for decades that suprasellar germinomas can
cause diabetes insipidus, visual disturbances, and pituitary
dysfunctions. Treatment protocols for CNS GCTs have evolved
greatly and the survival rate for germinomas is more than 90%,
whereas NGGCTs have a 10-year overall survival of 60-80% (7).
In most cases, these tumors are associated with permanent
endocrine disorders that must be continuously followed up (6).
Our patient was affected by non-germinomatous germ cell
tumor (NGGCT), based on alfa-fetoprotein, hCG levels in plasma
and CSF and based on histopathological examination. The girl had
secondary adrenal insufficiency, diabetes insipidus, central
hypothyroidism, hypothalamic obesity and GH deficiency.
How to manage patients with pituitary tumors without
easy access to full investigations in the COVID-19 era was
described by Fleseriu et al. (3) and the response to COVID-19
by endocrinologists and diabetologists has been described (8).
There is currently no proven concern that pituitary tumors per se
affect the immune system, apart from corticotropic adenomas
causing cortisol excess. Patients with uncontrolled Cushing’s
disease are at higher risk of infections, which affects their
mortality risk (9). Moreover, those patients may be taking
supraphysiologic doses of glucocorticoids and might be more
susceptible to COVID-19 as a result of the immunosuppressive
effects of steroids.Frontiers in Endocrinology | www.frontiersin.org 4Our patient had long suspended the high antiedema doses of
dexamethasone at the time of infection and she was taking
replacement doses of hydrocortisone. We presumed that she
was infected through contact with her father at home, and she
tested positive regardless of the therapies she was taking.
The impact of COVID-19 on patients with pituitary-
neuroendocrine disease also needs to be considered. Included in
the management of a patient with hypopituitarism are
replacement of hormone deficiencies, regular screening for the
development of new pituitary hormone deficiencies, surveillance
of the underlying cause (usually a tumor). Many of these patients
have hypopituitarism including secondary adrenal insufficiency,
requiring stress dose glucocorticoid supplementation in adult
patients and in children (10). Also, patients with adrenal
insufficiency are at increased risk of infection (11), which may
be complicated by developing an adrenal crisis. However, there is
currently no evidence that adrenal insufficiency patients are more
likely to develop a severe course of the viral disease. Adrenal crisis
occurs when cortisol availability is reduced or low at a time of
increased need for cortisol, such as during a severe infection (e.g.
influenza or viral respiratory infection). Therefore, to prevent
adrenal crisis patients are instructed to immediately double or
triple their daily dose of hydrocortisone during an illness, whereas
the dose adjustment during a stress not related to illness.
Our young patient never showed signs or symptoms indicating
clinical deterioration, which in patients affected by COVID-19,
typically occur 7-10 days after the onset of the first COVID-
associated symptoms. Our report confirms that an asymptomatic
child, who tested SARS-CoV-2 positive, for example through
family or oncology screening, does not need to increase their
routine hydrocortisone replacement dose. However, we stress that,
in case of an acute COVID-19 infection with clinical deterioration,
children with adrenal insufficiency should immediately receive a
parenteral injection of 50-100 mg/m2 hydrocortisone (usually 25
mg for infants, 50 mg for school children) (12).
No published reports so far have reported a higher prevalence
of dysnatremia in COVID-19. However, the COVID-19
pandemic has limited the accessibility of blood testing, and the
priority of routine treatment of central DI should be to avoid
hyponatremia. It emphasizes the importance of delaying
desmopressin doses, to allow regular periods of free water
clearance, so that excess water intake does not lead to
dilutional hyponatremia (13). Our patient had adipsic DI and















7 days before 290 145
Day 0 (8:00 am) 286 143 96 235
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Day +1 (8:00 am) 293 143 <20 68 4 <0,005 16,3
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Day + 3 (8:00 am) 283 138 143 587
Day + 20(I negative swab)
Day + 28 (II negative swab) 280 136 124 718March 2021 | Volume 12 | ArticlTABLE 3 | Nasopharyngeal swabs with cycle threshold (Ct) value results.
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outcome in patients with Covid-19 (1). Therefore, our patient
could have been among the most vulnerable; she had a very
close follow-up for the superimposed illness without, however,
manifesting imbalance.
Data on thyroid function or thyroid pathology are not yet
ava i lab le in COVID-19 . Pat ients wi th under ly ing
hypothyroidism or hyperthyroidism are advised to continue
their prescribed medications as usual (14). Our patient, with
central hypothyroidism, in agreement with the British Thyroid
Association and the Society for Endocrinology (BTA/SfE)
consensus statement, did not change the usual dose of
levothyroxine during the SARS-CoV-2 infection. Due to the
recent diagnosis, despite her GH deficiency, our patient at the
time of the SARS-CoV-2 infection had not yet started treatment.
Although infections can cause GH deficiency (15), there is no
data in the literature on the increased risk of infections in
patients with GH deficiency. Critical illness induced a rise in
GH and IGFBP1 and a fall in IGF-I and IGFBP3, as previously
described. Unfortunately, during the SARS-CoV-2 infection, we
did not perform our patient’s the dosage of GH or IGF-1
considered in the emergency to be of secondary importance.
Finally, the first systematic review dealing with the impact of
immunosuppression on SARS-CoV-2 infection affirmed that
immunosuppressed hosts may not present a greater risk of an
increased severity of disease, compared to the general population
(16). Considering instead, the evidence available to date on
SARS-CoV-2 infect ion outcomes in pat ients wi th
immunosuppression (either due to their disease or the use of
immunosuppressants) its behavior is not clear. The patients with
cancer and recent treatment of cancer (chemotherapy or surgery)
have a higher risk of worse outcomes, with faster deterioration
than those without cancer, an increased risk of severity and
mortality having been shown through two meta-analyses. This
could perhaps be explained in that the severity of SARS-CoV-2
infection has been associated with an aberrant inflammatory
response (cytokine storm) (17). To increase our knowledge in
disease mechanisms, we need to learn from clinical and
immunologic characteristics of patients with severe in contrast
to moderate disease. We interrupted the conditioning regimen in
our patient because at the time of diagnosis of infection there was
no consensus about chemotherapy in similar patients SARS-
CoV-2 positive. In addition, her ASCT was not considered
urgent, so it was reasonable to delay the treatment after the
negativity of NPS. For these reasons, the strength of our
description is the need to inform the scientific community
about this case report. The major merits were detecting
novelties, pharmacovigilance and high applicability when other
research designs were difficult to carry out. The major limitations
were the lack of ability to generalize and the retrospective design.MANAGEMENT RECOMMENDATIONS
During this COVID-19 pandemic, in children with
hypopituitarism, proper methods for viral respiratory infectionFrontiers in Endocrinology | www.frontiersin.org 5control and prevention, supportive therapies, and considerations
of potential therapies relevant to the pituitary disorders and any
underlying comorbidities should be undertaken. The caregivers
are urged to request for COVID-19 testing for patients if
exposed. Even if symptoms are mild or if fever is present
contacting the team (the physicians or nurse by telephone, e-
mail, or telemedicine) is mandatory in order to seek medical
guidance. Maintain of adequate hydration, adhere to daily
medications, and adapt to increased replacement dosages if
clinically indicated, is recommended.PATIENT PERSPECTIVE
Recognizing SARS-CoV-2 as a possible causal trigger of
endocrinological failure and its exacerbation is of particular
importance to improving its early diagnosis. In addition, the
aim of our report is to be informative while reassuring at the
same time. Our case suggests that SARS-CoV-2-infection is
usually mild and self-limiting in children even in those who
are immunocompromised. Patients are advised to keep any
scheduled appointments unless informed otherwise.DATA AVAILABILITY STATEMENT
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